Header Logo

Connection

CARL ALLEN to Histiocytosis, Langerhans-Cell

Back to Details
This is a "connection" page, showing publications CARL ALLEN has written about Histiocytosis, Langerhans-Cell.
CARL ALLEN
Connection Strength
13.447
Histiocytosis, Langerhans-Cell
  1. Histiocytic Disorders of Childhood. Pediatr Rev. 2022 Oct 01; 43(10):561-571.
    View in: PubMed
    Score: 0.671
  2. Langerhans cell histiocytosis: Version 2021. Hematol Oncol. 2021 Jun; 39 Suppl 1:15-23.
    View in: PubMed
    Score: 0.612
  3. Langerhans cell histiocytosis. Blood. 2020 04 16; 135(16):1319-1331.
    View in: PubMed
    Score: 0.566
  4. Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Adv. 2020 01 14; 4(1):87-99.
    View in: PubMed
    Score: 0.556
  5. The coming of age of Langerhans cell histiocytosis. Nat Immunol. 2020 01; 21(1):1-7.
    View in: PubMed
    Score: 0.555
  6. Langerhans-Cell Histiocytosis. N Engl J Med. 2018 08 30; 379(9):856-868.
    View in: PubMed
    Score: 0.506
  7. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.492
  8. A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood. 2017 11 16; 130(20):2229-2232.
    View in: PubMed
    Score: 0.474
  9. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016 11 24; 128(21):2533-2537.
    View in: PubMed
    Score: 0.444
  10. Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications. Oncology (Williston Park). 2016 Feb; 30(2):122-32, 139.
    View in: PubMed
    Score: 0.423
  11. Cell(s) of Origin of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015 Oct; 29(5):825-38.
    View in: PubMed
    Score: 0.410
  12. How I treat Langerhans cell histiocytosis. Blood. 2015 Jul 02; 126(1):26-35.
    View in: PubMed
    Score: 0.399
  13. Treatment of Langerhans cell histiocytosis: it is time to learn from the past: response to Minkov and Rodriguez-Galindo. Br J Haematol. 2015 Oct; 171(1):150-1.
    View in: PubMed
    Score: 0.399
  14. Pediatric lymphomas and histiocytic disorders of childhood. Pediatr Clin North Am. 2015 Feb; 62(1):139-65.
    View in: PubMed
    Score: 0.395
  15. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematology Am Soc Hematol Educ Program. 2015; 2015:559-64.
    View in: PubMed
    Score: 0.392
  16. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2015 Apr; 169(1):3-13.
    View in: PubMed
    Score: 0.390
  17. Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol. 2015 Apr; 169(2):299-301.
    View in: PubMed
    Score: 0.389
  18. Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr. 2014 Nov; 165(5):990-6.
    View in: PubMed
    Score: 0.387
  19. Neither IL-17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions. Mol Ther. 2011 Aug; 19(8):1433-9.
    View in: PubMed
    Score: 0.306
  20. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010 Apr 15; 184(8):4557-67.
    View in: PubMed
    Score: 0.281
  21. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010 Mar; 54(3):416-23.
    View in: PubMed
    Score: 0.281
  22. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med. 2009 May; 15(5):483-4; author reply 484-5.
    View in: PubMed
    Score: 0.265
  23. Langerhans cell histiocytosis: a review of past, current and future therapies. Drugs Today (Barc). 2007 Sep; 43(9):627-43.
    View in: PubMed
    Score: 0.236
  24. Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024 Jul 15; 130(14):2416-2439.
    View in: PubMed
    Score: 0.187
  25. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.186
  26. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1882-1887.
    View in: PubMed
    Score: 0.186
  27. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders. Immunity. 2023 12 12; 56(12):2790-2802.e6.
    View in: PubMed
    Score: 0.182
  28. Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30565.
    View in: PubMed
    Score: 0.177
  29. Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis. Blood Adv. 2023 05 23; 7(10):2171-2176.
    View in: PubMed
    Score: 0.175
  30. Cellular distribution of mutations and association with disease risk in?Langerhans cell histiocytosis without BRAFV600E. Blood Adv. 2022 08 23; 6(16):4901-4904.
    View in: PubMed
    Score: 0.167
  31. Prevalence of the BRAFV600E mutation in Greek adults with Langerhans cell histiocytosis. Pediatr Hematol Oncol. 2022 Sep; 39(6):540-548.
    View in: PubMed
    Score: 0.161
  32. Histiocytic disorders. Nat Rev Dis Primers. 2021 10 07; 7(1):73.
    View in: PubMed
    Score: 0.157
  33. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021 05; 27(5):851-861.
    View in: PubMed
    Score: 0.152
  34. Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021 04 01; 137(13):1777-1791.
    View in: PubMed
    Score: 0.151
  35. BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice. Blood Adv. 2020 10 13; 4(19):4912-4917.
    View in: PubMed
    Score: 0.146
  36. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.130
  37. The role of parental and perinatal characteristics on Langerhans cell histiocytosis: characterizing increased risk among Hispanics. Ann Epidemiol. 2018 08; 28(8):521-528.
    View in: PubMed
    Score: 0.123
  38. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 01 02; 215(1):319-336.
    View in: PubMed
    Score: 0.120
  39. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018 Jan; 65(1).
    View in: PubMed
    Score: 0.119
  40. New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Mol Cancer. 2017 07 06; 16(1):115.
    View in: PubMed
    Score: 0.117
  41. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 07 13; 130(2):167-175.
    View in: PubMed
    Score: 0.116
  42. The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis. Hematol Oncol. 2018 Feb; 36(1):307-315.
    View in: PubMed
    Score: 0.114
  43. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.111
  44. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.111
  45. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016 06 02; 127(22):2672-81.
    View in: PubMed
    Score: 0.106
  46. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
    View in: PubMed
    Score: 0.096
  47. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 07; 211(4):669-83.
    View in: PubMed
    Score: 0.093
  48. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014 Mar; 61(3):479-87.
    View in: PubMed
    Score: 0.090
  49. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012; 7(8):e43257.
    View in: PubMed
    Score: 0.083
  50. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan; 52(1):97-101.
    View in: PubMed
    Score: 0.065
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.